Process for the reductive alkylation of normorphinans
View Patent ↗The invention provides a process for the N-alkylation of normorphinan compounds to produce N-alkylated morphinan compounds. In particular, the process relates to the alkylation of a normorphinan compound by a carboxaldehyde in the presence of a reducing agent to form an N-alkylated morphinan.
1. A process for the preparation of an N-alkylated morphinan having NR 10 at position 17, the process comprising contacting a normorphinan having a secondary amine at position 17 with an alkylating agent having R 10 , wherein R 10 is chosen from hydrocarbyl and substituted hydrocarbyl, a proton acceptor, and a reducing agent chosen from formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof to form the N-alkylated morphinan having NR 10 at position 17, wherein the process occurs without the use of a transition metal catalyst.
2. The process of claim 1 , wherein the reaction forming the N-alkylated morphinan having NR 10 at position 17 is conducted in a one-pot process.
3. The process of claim 1 , wherein the normorphinan is chosen from norcodeine, normorphine, northebaine, nororipavine, noroxymorphone, nordihydromorphine, nordihydrocodeine, norhydrocodone, norhydromorphone, noroxycodone, nordextromethorphan, nordextrorphan, norlevomethorphan, norlevorphanol, norbuprenorphine, noroxymomorphol, noroxycodol, norsinomenine, and nordihydrosinomenine; the N-alkylated morphinan is chosen from codeine, morphine, thebaine, oripavine, oxymorphone, dihydromorphone, dihydrocodeine, hydrocodone, hydromorphone, oxycodone, oxycodeinone, naloxone, naltrexone, nalbuphine, nalmefene, nalfurafine, morphinone, ethylmorphine, butorphanol, dextromethorphan, dextrorphan, levomethorphan, levorphanol, buprenorphine, sinomenine, and dihydrosinomenine; the alkylating agent is an aldehyde; and R 10 is chosen from alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, and aryl.
4. The process of claim 1 , wherein the normorphinan is chosen from norcodeine, normorphine, northebaine, noroxymorphone, nordihydromorphine, nordihydrocodeine, norhydrocodone, norhydromorphone, noroxycodone, nordextromethorphan, nordextrorphan, norlevomethorphan, norlevorphanol, norsinomenine, and nordihydrosinomenine; the proton acceptor is triethylamine; the alkylating agent is an aldehyde, and R 10 is chosen from alkyl, cycloalkyl, cycloalkylmethyl, alkenyl, alkynyl, and aryl.
5. The process of claim 1 , wherein an intermediate compound of an iminium salt of the normorphinan is formed in the reaction prior to the formation of the N-alkylated morphinan.
6. The process of claim 5 , wherein the N-alkylated morphinan is Formula (IIIa), the process comprising:
(a) contacting a compound of Formula (Ia) with the alkylating agent having R 10 in the presence of a proton acceptor to form a compound of Formula (IIa); and
(b) contacting the compound of Formula (IIa) with the reducing agent chosen from formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof, to form the compound of Formula (IIIa) according to the following reaction scheme:
wherein:
R 2 , R 6 , and R 7 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and {—}OR 11 ;
R 3 , and R 4 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and {—}OR 11 ;
R 5 is chosen from hydrogen, and hydroxyl;
R 8 is chosen from {═}O, and hydroxyl;
R 10 is chosen from hydrocarbyl, and substituted hydrocarbyl;
R 11 is chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxyl protecting group; and
X is chosen from oxygen and sulfur.
7. The process of claim 6 , wherein R 3 , R 4 , R 6 , and R 7 are hydrogen, R 8 is {═}O, R 10 is a cycloalkyl group, and X is oxygen.
8. The process of claim 6 , wherein R 3 , R 4 , R 8 , and R 7 are hydrogen, R 8 is a hydroxyl group, R 10 is a cycloalkylmethyl group, and X is oxygen.
9. The process of claim 6 , wherein the alkylating agent is an aldehyde of the formula R 10 CHO, the reducing agent is formic acid, and the reaction is performed in the presence of a protic solvent.
10. The process of claim 6 , wherein the proton acceptor is triethylamine; the alkylating agent is a carboxaldehyde, R 10 is selected from the group consisting of cyclopropylmethyl and cyclobutylmethyl; and the reaction is conducted in the presence of a protic solvent comprising an alcohol group.
11. The process of claim 6 , wherein the reaction is conducted in a one-pot process.
12. The process of claim 6 , wherein the optical activity of compounds of Formulas (Ia), (IIa), and (IIIa) is (−) or (+), and the configuration of carbons 5, 13, 14, and 9, respectively, is chosen from RRRR, RRRS, RRSR, RSRR, SRRR, RRSS, RSSR, SSRR, SRRS, SRSR, RSRS, RSSS, SRSS, SSRS, SSSR, and SSSS, provided that the carbons at positions 15 and 16 are both either on the alpha face of the molecule or the beta face of the molecule.
13. The process of claim 5 , wherein the N-alkylated morphinan is Formula (IIIb), the process comprising:
(a) contacting a compound of Formula (Ib) with the alkylating agent having R 10 in the presence of a proton acceptor to form a compound of Formula (IIb); and
(b) contacting the compound of Formula (IIb) with the reducing agent chosen from formic acid, methyl formate, formamide, a mixture of formic acid and an alkali salt of formic acid, and combinations thereof to form the compound comprising of Formula (IIIb) according to the following reaction scheme:
wherein:
R 1 , R 2 , R 6 , and R 7 , and R 9 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and {—}OR 11 ;
R 3 , and R 4 are independently chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, and {—}OR 11 ;
R 5 is chosen from hydrogen, and hydroxyl;
R 8 is chosen from {═}O, and hydroxyl;
R 10 is chosen from hydrocarbyl, and substituted hydrocarbyl; and
R 11 is chosen from hydrogen, hydrocarbyl, substituted hydrocarbyl, and a hydroxyl protecting group.
14. The process of claim 13 , wherein R 1 , R 3 , R 4 , R 6 , R 7 , and R 9 are hydrogen, R 8 is {—}O, and R 10 is a cycloalkyl group.
15. The process of claim 13 , wherein R 1 , R 3 , R 4 , R 6 , R 7 , and R 9 are hydrogen, R 8 is a hydroxyl group, and R 10 is a cycloalkylmethyl group.
16. The process of claim 13 , wherein the alkylating agent is an aldehyde of the formula R 10 CHO, the reducing agent is formic acid, and the reaction is performed in the presence of a protic solvent.
17. The process of claim 13 , wherein the proton acceptor is triethylamine; the alkylating agent is a carboxaldehyde, R 10 is chosen from cyclopropylmethyl and cyclobutylmethyl; and the reaction is conducted in the presence of a protic solvent comprising an alcohol group.
18. The process of claim 13 , wherein the reaction is conducted in a one-pot process.
19. The process of claim 13 , wherein the optical activity of compounds of Formulas (Ib), (IIb), and (IIIb) is (−) or (+) and the configuration of C13, C14, and C9, respectively, is chosen from RRR, RRS. RSR, SRR, SRS, SSR, RSS, and SSS, provided that the carbons at positions 15 and 16 are both either on the alpha face of the molecule or the beta face of the molecule.
20. The process of claim 1 , wherein the process comprises forming an initial reaction mixture consisting of the normorphinan, the alkylating agent, the proton acceptor, the reducing agent and a solvent.